Buy Abbott India; target of Rs 22,780: Sharekhan

The research firm ICICI Securities believes earnings of apparel brands and retail companies under their coverage may surprise positively from Q3FY22E as the likely demand recovery may result in better than expected margin performance. Some of the costs savings achieved during pandemic may sustain and coupled with high operating leverage may lead to higher than pre-covid margins from Q3FY22E.  Stocks like Trent, V-Mart and Aditya Birla Fashion and Retail are the preferred picks backed by their strong and consistent track record of execution.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Sharekhan's research report on Abbott India

Abbott India Limited (Abbott) reported steady performance for Q1FY23, but results missed estimates. Revenues and earnings to clock a strong 10% and 14% CAGR over FY2022E-FY2024E. Double-digit growth in IPM is expected to sustain going ahead driven by multiple growth drivers and sizeable contribution from acute therapies. Healthy growth prospects, a strong, debt-free balance sheet and strong dividend payout are key positives for Abbott.

Outlook

We maintain a Buy on the stock with an unchanged PT of Rs. 22,780.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Abbott India - 110822 - khan